Lanfeng Biochemical released its 2026 interim report. Total operating revenue was 1.261 billion yuan, and net profit attributable to the parent company was a loss of 59.8 million yuan, a decrease of 15.02 million yuan compared with the same period last year, with the loss widening year-on-year. Net cash flow from operating activities was negative 1.14 million yuan. The asset-liability ratio rose to 92.99%, gross margin fell to 3.46%, return on equity was negative 1199.27%, and diluted earnings per share was negative 0.16 yuan. The company had 26,900 shareholders, and the top ten shareholders held 41.44% of total share capital.
Jiangsu Lanfeng Bio-chemical Co LtdNet loss widened year-on-year, with deteriorating margins and high leverage.
